IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Chiu
Weldon
W
Pullon
Humphrey
H
Woon
See-Tarn
ST
Oei
Paul
P
The
Roy
R
Ameratunga
Rohan
R
D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000473:pathology; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007070:Immunoglobulin A / Q000097:blood*; D007073:Immunoglobulin E / Q000097:blood*; D007145:Immunoglobulin kappa-Chains / Q000097:blood*; D007952:Leukemia, Plasma Cell / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D009194:Myeloma Proteins / Q000032:analysis*; D016609:Neoplasms, Second Primary; D011241:Prednisone / Q000627:therapeutic use; D000077211:Zoledronic Acid
D018906:Antineoplastic Agents, Alkylating; D004164:Diphosphonates; D007093:Imidazoles; D007070:Immunoglobulin A; D007145:Immunoglobulin kappa-Chains; D009194:Myeloma Proteins; D007073:Immunoglobulin E; D000077211:Zoledronic Acid; D008558:Melphalan; D011241:Prednisone